


Stereochemistry abstracts

Gabriela Guillena, María del Carmen Hita and Carmen Nájera*

Tetrahedron: Asymmetry 17 (2006) 729



C₃₀H₃₀N₄O₂

(2*S*)-*N*-(1-((*S*)-2-((*S*)-Pyrrolidine-2-carboxamido)naphthalen-1-yl)naphthalen-2-yl)pyrrolidine-2-carboxamide


[α]_D²⁶ = -108.6 (*c* 1, MeOH)

Source of chirality: Commercially available
(*Sa*)-BINAM

Absolute configuration: *Sa*, *S*

Gabriela Guillena, María del Carmen Hita and Carmen Nájera*

Tetrahedron: Asymmetry 17 (2006) 729



C₃₀H₃₀N₄O₂

(2*R*)-*N*-(1-((*S*)-2-((*S*)-Pyrrolidine-2-carboxamido)naphthalen-1-yl)naphthalen-2-yl)pyrrolidine-2-carboxamide


[α]_D²⁵ = +6.7 (*c* 1, MeOH)

Source of chirality: Commercially available
(*Ra*)-BINAM

Absolute configuration: *Ra*, *S*

Gabriela Guillena, María del Carmen Hita and Carmen Nájera*

Tetrahedron: Asymmetry 17 (2006) 729



C₂₅H₂₃N₃O

(2*S*)-*N*-(*S*)-1-(2-Aminonaphthalen-1-yl)naphthalen-2-yl)pyrrolidine-2-carboxamide

[α]_D²⁹ = -87.4 (*c* 1, MeOH)

Source of chirality: Commercially available
(*Sa*)-BINAM

Absolute configuration: *Sa*, *S*

Samik Nanda, Yasuo Kato and Yasuhisa Asano*


Tetrahedron: Asymmetry 17 (2006) 735

Ee = 97%

[α]_D²⁵ = -31.1 (*c* 1.4, CHCl₃)


Source of chirality: asymmetric hydrocyanation

Absolute configuration: 2*R*



C₈H₁₁ON

(2*R*,3*E*,5*E*)-2-Hydroxy-3,5-octadienenitrile




(2R)-2-Cyclobutyl-2-hydroxyacetonitrile

Ee = 92%

$[\alpha]_D^{25} = +3.8$ (*c* 1.1, CHCl₃)

Source of chirality: asymmetric hydrocyanation

Absolute configuration: 2*R*




(2R)-2-Cyclopentyl-2-hydroxyacetonitrile

Ee = 94%

$[\alpha]_D^{25} = +11.2$ (*c* 1.0, CHCl₃)

Source of chirality: asymmetric hydrocyanation

Absolute configuration: 2*R*




(2R)-2-Cyclohexenyl-2-hydroxyacetonitrile

Ee = 90%

$[\alpha]_D^{25} = -16.7$ (*c* 1.5, CHCl₃)

Source of chirality: asymmetric hydrocyanation

Absolute configuration: 2*R*




(2R)-2-Hydroxy-2-(6,6-dimethylbicyclo[3.1.1]hept-2-en-3-yl)acetonitrile

Ee = 99%


$[\alpha]_D^{25} = -21.1$ (*c* 1.4, CHCl₃)

Source of chirality: asymmetric hydrocyanation


Absolute configuration: 2*R*

(2*R*,*3E*)-3-Ethyl-2-hydroxy-3-pentenenitrile $Ee = 92\%$ $[\alpha]_D^{25} = -32.1 (c\ 1.0, \text{CHCl}_3)$


Source of chirality: asymmetric hydrocyanation

Absolute configuration: 2*R*(2*R*,*3E*)-2-Hydroxy-3-octenenitrile $Ee = 72\%$ $[\alpha]_D^{25} = -16.3 (c\ 1.0, \text{CHCl}_3)$

Source of chirality: asymmetric hydrocyanation


Absolute configuration: 2*R*(2*R*,*3E*)-2-Hydroxy-3-methyl-3-hexenenitrile $Ee = 96\%$ $[\alpha]_D^{25} = -26.8 (c\ 1.2, \text{CHCl}_3)$

Source of chirality: asymmetric hydrocyanation




Absolute configuration: 2*R*(2*R*,*3E*)-3-Ethyl-2-hydroxy-3-heptenenitrile $Ee = 92\%$ $[\alpha]_D^{25} = -36.8 (c\ 1.0, \text{CHCl}_3)$


Source of chirality: asymmetric hydrocyanation

Absolute configuration: 2*R*



 $C_{14}H_{15}NO$ 2-Methyl-1-((1S)-1-phenylethyl)-1*H*-pyrrole-3-carbaldehyde $[\alpha]_D^{25} = -21.9$ (*c* 0.8, CHCl₃)

Source of chirality: (S)-1-phenylethylamine

 $C_{23}H_{28}N_2O$ (1S,2R)-2-((2-Methyl-1-((1S)-1-phenylethyl)-1*H*-pyrrol-3-yl)methylamino)-1-phenylpropan-1-ol $[\alpha]_D^{25} = +3.7$ (*c* 11, CHCl₃)Source of chirality: (1*S*,2*R*)-norephedrine,
(*S*)-2-methyl-1-(1-phenylethyl)-1*H*-pyrrole $C_{23}H_{28}N_2O$ (1*S*,2*R*)-2-((2-Methyl-1-((1*R*)-1-phenylethyl)-1*H*-pyrrol-3-yl)methylamino)-1-phenylpropan-1-ol $[\alpha]_D^{25} = +5.6$ (*c* 7.3, CHCl₃)Source of chirality: (1*S*,2*R*)-norephedrine,
(*R*)-2-methyl-1-(1-phenylethyl)-1*H*-pyrrole $C_{14}H_{15}NO$ 5-Methyl-1-((1S)-1-phenylethyl)-1*H*-pyrrole-2-carbaldehyde $[\alpha]_D^{25} = -118.9$ (*c* 11, CHCl₃)Source of chirality: (*R*)-1-phenylethylamine

 $C_{23}H_{28}N_2O$


(1S,2R)-2-((5-Methyl-1-((1S)-1-phenylethyl)-1H-pyrrol-2-yl)methylamino)-1-phenylpropan-1-ol

 $[\alpha]_D^{27} = +28.2$ (*c* 11, CHCl₃)Source of chirality: (1*S*,2*R*)-norephedrine, (*S*)-2-methyl-1-(1-phenylethyl)-1*H*-pyrrole $C_{23}H_{28}N_2O$ (1*S*,2*R*)-2-((5-Methyl-1-((1*R*)-1-phenylethyl)-1*H*-pyrrol-2-yl)methylamino)-1-phenylpropan-1-ol $[\alpha]_D^{27} = +20.6$ (*c* 15.7, CHCl₃)Source of chirality: (1*S*,2*R*)-norephedrine, (*R*)-2-methyl-1-(1-phenylethyl)-1*H*-pyrrole $C_{15}H_{12}O_2$ (2*R*,3*S*)-Phenyl(-3-phenyloxiran-2-yl)methanone

Ee = 74%

 $[\alpha]_D^{23} = -116.3$ (*c* 0.40, CHCl₃)

Source of chirality: asymmetric oxidation


Absolute configuration: (2*R*,3*S*) $C_{15}H_{11}ClO_2$ ((2*R*,3*S*)-3-(4-Chlorophenyl)oxiran-2-yl)(phenyl)methanone

Ee = 73%

 $[\alpha]_D^{23} = -164.9$ (*c* 0.40, CHCl₃)

Source of chirality: asymmetric oxidation

Absolute configuration: (2*R*,3*S*)



C₁₅H₁₁ClO₂


(2*R*,3*S*)-(4-Chlorophenyl)(-3-phenyloxiran-2-yl)methanone

Ee = 73%

[α]_D²³ = -66.8 (*c* 0.65, CHCl₃)

Source of chirality: asymmetric oxidation

Absolute configuration: (2*R*,3*S*)



C₁₅H₁₁FO₂


(2*R*,3*S*)-(4-Fluorophenyl)(-3-phenyloxiran-2-yl)methanone

Ee = 74%

[α]_D²³ = -92.5 (*c* 0.90, CHCl₃)

Source of chirality: asymmetric oxidation

Absolute configuration: (2*R*,3*S*)



C₁₅H₁₁NO₄


(2*R*,3*S*)-(4-Nitrophenyl)(-3-phenyloxiran-2-yl)methanone

Ee = 73%

[α]_D²³ = -99.6 (*c* 1.00, CHCl₃)

Source of chirality: asymmetric oxidation

Absolute configuration: (2*R*,3*S*)



C₂₁H₁₆O₂


(2*R*,3*S*)-Biphenyl-4-yl(-3-phenyloxiran-2-yl)methanone

Ee = 77%

[α]_D²³ = -85.6 (*c* 0.56, CHCl₃)

Source of chirality: asymmetric oxidation

Absolute configuration: (2*R*,3*S*)




C₁₅H₁₀ClFO₂
((2*R*,3*S*)-3-(4-Chlorophenyl)oxiran-2-yl)(4-fluorophenyl)methanone

Ee = 78%

[α]_D²³ = -66.8 (*c* 0.65, CHCl₃)

Source of chirality: asymmetric oxidation

Absolute configuration: (2*R*,3*S*)




C₁₅H₁₁ClO₂
((2*R*,3*S*)-3-(2-Chlorophenyl)oxiran-2-yl)(phenyl)methanone

Ee = 56%

[α]_D²³ = -105.8 (*c* 1.00, CHCl₃)

Source of chirality: asymmetric oxidation

Absolute configuration: (2*R*,3*S*)




C₁₀H₁₀O₂
1-((2*R*,3*S*)-3-Phenoxyiran-2-yl)ethanone

Ee = 69%

[α]_D²³ = -77.6 (*c* 1.00, CHCl₃)

Source of chirality: asymmetric oxidation


Absolute configuration: (2*R*,3*S*)



C₂H₂₂O₁₁
6-O-(β-D-Glucopyranosyl)-D-fructofuranose (gentiobiulose)


[α]_D²⁰ = +9.1 (*c* 1.0, H₂O)

Source of chirality: gentiobiose




$C_{28}H_{38}O_{19}$
Octa- O -acetyl- β -melibiose

$[\alpha]_D^{20} = +105$ (*c* 0.8, CHCl₃)




$C_{12}H_{16}O_8$
5-[(α -D-Galactopyranosyloxy)methyl]-2-furancarboxyaldehyde

$[\alpha]_D^{20} = +158$ (*c* 1, MeOH)
Source of chirality: melibiose



$C_{12}H_{16}O_8$
5-[(α -D-Glucopyranosyloxy)methyl]-2-furancarboxyaldehyde

$[\alpha]_D^{20} = -159$ (*c* 1, MeOH)
Source of chirality: gentiobiose




$C_{12}H_{16}O_9$
5-[(α -D-Galactopyranosyloxy)methyl]-2-furoic acid


$[\alpha]_D^{20} = +147$ (*c* 0.8, MeOH)
Source of chirality: melibiose

$[\alpha]_D^{20} = -35$ (*c* 1, MeOH)


Source of chirality: primeverose

 $C_{11}H_{14}O_7$ 5-[(α -D-Xylopyranosyloxy)methyl]-2-furancarboxyaldehyde $[\alpha]_D^{20} = +97$ (*c* 0.9, MeOH)


Source of chirality: isomaltulose

 $C_{12}H_{14}O_{10}$ 5-[(α -D-Glucopyranuronosyloxy)methyl]-2-furoic acid $[\alpha]_D^{20} = +108$ (*c* 0.7, MeOH)


Source of chirality: melibiose

 $C_{12}H_{14}O_{10}$ 5-[(α -D-Glactopyranuronosyloxy)methyl]-2-furoic acid $[\alpha]_D = +5.7$ (*c* 1, CHCl₃)


Source of chirality: L-serine

 $C_{17}H_{23}NO_5$


(S)-Benzyl 4-((R)-1-hydroxy-3-oxobutyl)-2,2-dimethyloxazolidine-3-carboxylate

 $C_{17}H_{25}NO_5$ (S)-Benzyl 4-((1*R*,3*R*)-1,3-dihydroxybutyl)-2,2-dimethyloxazolidine-3-carboxylate $[\alpha]_D = -13.2$ (*c* 1, CHCl₃)

Source of chirality: L-serine

 $C_{14}H_{21}NO_5$ Benzyl (2*S*,3*R*,5*S*)-1,3,5-trihydroxyhexan-2-ylcarbamate $[\alpha]_D = +6.6$ (*c* 0.5, MeOH)

Source of chirality: L-serine


 $C_{34}H_{36}N_2O_2$

3,3'-Bis[(4'S)-tert-Butyloxazolin-2'-yl]-2,2'-binaphthyl

 $[\alpha]_D^9 = -78.5$ (*c* 0.5, CHCl₃)

Source of chirality: (S)-(+)leucinol

Absolute configuration: (S)

 $C_{26}H_{30}Cl_2N_2O_2$

5,5'-Dichloro-2,2'-bis[(4'S)-tert-Butyloxazolin-2'-yl]-1,1'-biphenyl



 $[\alpha]_D^{13} = -96.6$ (*c* 0.5, CHCl₃)

Source of chirality: (S)-(+)leucinol

Absolute configuration: (S)

Wanbin Zhang,* Fang Xie, Shigeaki Matsuo, Yuji Imahori,
Toshiyuki Kida, Yohji Nakatsuji and Isao Ikeda*

Tetrahedron: Asymmetry 17 (2006) 767



5,5'-Diphenyl-2,2'-bis[(4'S)-isopropylloxazolin-2'-yl]-1,1'-biphenyl



$$[\alpha]_D^{13} = -59.0 \text{ (c } 0.5, \text{ CHCl}_3\text{)}$$

Source of chirality: (S)-(+) -valinol

Absolute configuration: (S)

Wanbin Zhang,* Fang Xie, Shigeaki Matsuo, Yuji Imahori,
Toshiyuki Kida, Yohji Nakatsuji and Isao Ikeda*

Tetrahedron: Asymmetry 17 (2006) 767



2,2'-Bis[(4'R)-(hydroxymethyl)oxazolin-2'-yl]-1,1'-biphenyl

$$[\alpha]_D^9 = +53.4 \text{ (c } 0.51, \text{ CHCl}_3\text{)}$$

Source of chirality: L-serine methyl ester

Absolute configuration: (R)

Wanbin Zhang,* Fang Xie, Shigeaki Matsuo, Yuji Imahori,
Toshiyuki Kida, Yohji Nakatsuji and Isao Ikeda*

Tetrahedron: Asymmetry 17 (2006) 767



2,2'-Bis[(4'R)-(methoxymethyl)oxazolin-2'-yl]-1,1'-biphenyl


$$[\alpha]_D^9 = +150.5 \text{ (c } 0.49, \text{ CHCl}_3\text{)}$$

Source of chirality: L-serine methyl ester

Absolute configuration: (R)

Wanbin Zhang,* Fang Xie, Shigeaki Matsuo, Yuji Imahori,
Toshiyuki Kida, Yohji Nakatsuji and Isao Ikeda*

Tetrahedron: Asymmetry 17 (2006) 767



2,2'-Bis[(4'R)-(ethoxymethyl)oxazolin-2'-yl]-1,1'-biphenyl


$$[\alpha]_D^9 = +116.4 \text{ (c } 0.51, \text{ CHCl}_3\text{)}$$

Source of chirality: L-serine methyl ester

Absolute configuration: (R)

Wanbin Zhang,* Fang Xie, Shigeaki Matsuo, Yuji Imahori,
Toshiyuki Kida, Yohji Nakatsuji and Isao Ikeda*

Tetrahedron: Asymmetry 17 (2006) 767



C₂₄H₂₈N₂O₄
2,2'-Bis[(4'S)-(dimethylhydroxymethyl)oxazolin-2'-yl]-1,1'-biphenyl


[α]_D²⁷ = +71.2 (*c* 0.70, CHCl₃)

Source of chirality: L-serine methyl ester

Absolute configuration: (S)

Wanbin Zhang,* Fang Xie, Shigeaki Matsuo, Yuji Imahori,
Toshiyuki Kida, Yohji Nakatsuji and Isao Ikeda*

Tetrahedron: Asymmetry 17 (2006) 767



C₂₆H₃₂N₂O₄
2,2'-Bis[(4'S)-(dimethylmethoxymethyl)oxazolin-2'-yl]-1,1'-biphenyl


[α]_D¹⁰ = +11.9 (*c* 0.50, CHCl₃)

Source of chirality: L-serine methyl ester

Absolute configuration: (S)

Angela Patti* and Sonia Pedotti

Tetrahedron: Asymmetry 17 (2006) 778



C₁₄H₁₆FeO₂
(S)-1-Ferrocenyl-3-hydroxybutan-1-one

Ee = >99% (chiral HPLC)


[α]_D = -25.0 (*c* 0.24, CHCl₃)

Source of chirality: kinetic resolution by lipase-catalyzed esterification

Absolute configuration: S

Angela Patti* and Sonia Pedotti

Tetrahedron: Asymmetry 17 (2006) 778




C₁₆H₁₈FeO₃
(R)-1-Ferrocenyl-3-acetoxybutan-1-one

Ee = >99% (chiral HPLC)

[α]_D = +91.7 (*c* 0.63, CHCl₃)

Source of chirality: kinetic resolution by lipase-catalyzed esterification

Absolute configuration: R




$C_{14}H_{18}FeO_2$
(1*S*,*S*)-1-Ferrocenyl-1,3-dihydroxybutane

Ee = >99% (chiral HPLC)

$[\alpha]_D = +27.0$ (*c* 0.75, $CHCl_3$)

Source of chirality: enantiopure starting material

Absolute configuration: 1*S*,*S*




$C_{14}H_{18}FeO_2$
(1*R*,*S*)-1-Ferrocenyl-1,3-dihydroxybutane

Ee = >99% (chiral HPLC)

$[\alpha]_D = -11.8$ (*c* 0.68, $CHCl_3$)

Source of chirality: enantiopure starting material

Absolute configuration: 1*R*,*S*




$C_{18}H_{22}FeO_4$
(1*S*,*S*)-1-Ferrocenyl-1,3-diacetoxybutane

Ee = >99%

$[\alpha]_D = +77.9$ (*c* 1.10, $CHCl_3$)

Source of chirality: enantiopure starting material

Absolute configuration: 1*S*,*S*




$C_{18}H_{22}FeO_4$
(1*R*,*S*)-1-Ferrocenyl-1,3-diacetoxybutane

Ee = >99%

$[\alpha]_D = -49.5$ (*c* 0.90, $CHCl_3$)

Source of chirality: enantiopure starting material

Absolute configuration: 1*R*,*S*




$C_{16}H_{19}FeN_3O_2$
(1*S*,*S*)-1-Ferrocenyl-1-azido-3-acetoxybutane

Ee = >99%

 $[\alpha]_D = +26.6$ (*c* 0.90, CHCl₃)

Source of chirality: enantiopure starting material


Absolute configuration: 1*S*,*S*

$C_{16}H_{19}FeN_3O_2$
(1*R*,3*S*)-1-Ferrocenyl-1-azido-3-acetoxybutane

Ee = >99%

 $[\alpha]_D = -70.7$ (*c* 1.20, CHCl₃)

Source of chirality: enantiopure starting material


Absolute configuration: 1*R*,3*S*

$C_{14}H_{19}FeNO$
(1*S*,3*S*)-1-Ferrocenyl-1-amino-3-hydroxybutane

Ee = >99%

 $[\alpha]_D = +20.5$ (*c* 0.53, EtOH)

Source of chirality: enantiopure starting material

Absolute configuration: 1*S*,3*S*

$C_{14}H_{19}FeNO$
(1*R*,3*S*)-1-Ferrocenyl-1-amino-3-hydroxybutane

Ee = >99%

 $[\alpha]_D = -6.9$ (*c* 0.42, EtOH)


Source of chirality: enantiopure starting material

Absolute configuration: 1*R*,3*S*

Ee = 97%

 $[\alpha]_D^{25} = -140$ (*c* 0.5, CHCl₃)

Source of chirality: enzymatic resolution


C₁₀H₁₄O₄

(-)-3-Methoxy-4-methyl-2-oxocyclohex-3-enyl acetate

Ee = 76%

 $[\alpha]_D^{25} = -39.5$ (*c* 0.6, CHCl₃)

Source of chirality: enzymatic resolution


C₁₂H₁₈O₄

(+)-3-Methoxy-4,6,6-trimethyl-2-oxocyclohex-3-enyl acetate

Ee = 90%

 $[\alpha]_D^{25} = +81.6$ (*c* 0.2, CHCl₃)

Source of chirality: enzymatic resolution


C₈H₁₂O₃

(+)-6-Hydroxy-2-methoxy-3-methylcyclohex-2-en-1-one

Ee = 99%

 $[\alpha]_D^{25} = +111$ (*c* 0.3, CHCl₃)

Source of chirality: enzymatic resolution


C₁₀H₁₆O₃

(+)-6-Hydroxy-2-methoxy-3,5,5-trimethylcyclohex-2-en-1-one

Ee = 87%

 $[\alpha]_D^{25} = +10.6$ (*c* 0.8, CHCl₃)

Source of chirality: enzymatic resolution


C₉H₁₂O₄

(+)-3-Methoxy-4-methyl-2-oxocyclopent-3-enyl acetate

Ee = 93%

 $[\alpha]_D^{20} = +32.1$ (*c* 1, CHCl₃)

Source of chirality: enzymatic resolution


C₁₀H₁₄O₄

(+)-4-Ethyl-3-methoxy-2-oxocyclopent-3-enyl acetate

Ee = 96%

 $[\alpha]_D^{20} = -9.6$ (*c* 0.8, CHCl₃)

Source of chirality: enzymatic resolution


C₇H₁₀O₃

(-)-5-Hydroxy-3-methyl-2-methoxy-2-cyclopentene-1-one


Ee = 95%

 $[\alpha]_D^{20} = +15.2$ (*c* 0.8, CHCl₃)

Source of chirality: enzymatic resolution

C₈H₁₂O₃

(+)-3-Ethyl-5-hydroxy-2-methoxy-2-cyclopentene-1-one



C₉H₁₄O₂


1-((1*R*,6*R*)-6-Hydroxy-4-methylcyclohex-3-enyl)ethanone

Ee = 86%

[α]_D²⁰ = -158.4

Source of chirality: enzymatic resolution

Absolute configuration: 1*R*,6*R*



C₁₁H₁₆O₃


(1*R*,6*R*)-6-Acetyl-3-methylcyclohex-3-enyl acetate

Ee = 86%

[α]_D²⁰ = 131.8

Source of chirality: enzymatic resolution

Absolute configuration: 1*R*,6*R*



C₁₂H₁₈O₂


(1*R*,6*S*)-3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-enyl acetate

Ee = 98%

[α]_D²⁰ = -29.3

Source of chirality: enzymatic resolution

Absolute configuration: 1*R*,6*S*



C₁₀H₁₆O


(1*R*,6*S*)-3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-enol

Ee = 98%

[α]_D²⁰ = -53.0

Source of chirality: enzymatic resolution

Absolute configuration: 1*R*,6*S*




C₁₀H₁₄O
(S)-3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-enone

Ee = 98%

[α]_D²⁰ = -127.2

Source of chirality: enzymatic resolution

Absolute configuration: 1S




C₁₀H₁₆O
(1S,6S)-3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-enol

Ee = 98%

[α]_D²⁰ = -5.1

Source of chirality: enzymatic resolution

Absolute configuration: 1S,6S




C₉H₁₀O
(S)-(+)-1-Indanol

Ee >99% by HPLC on (Chiralcel® OD-H) column

[α]_D²⁰ = +16.7 (c 1, MeOH)

Source of chirality: asymmetric catalysis

Absolute configuration: S




C₁₀H₁₂O
(S)-(+)-1,2,3,4-Tetrahydro-1-naphthalenol

Ee >99% by HPLC on (Chiralcel® OB-H) column

[α]_D²⁰ = +28.1 (c 2, MeOH)

Source of chirality: asymmetric catalysis

Absolute configuration: S




C₁₂H₁₂O
(S)-(-)-1-(2-Naphthyl)ethanol

Ee >99% by HPLC on (Chiralcel® OD-H) column

$[\alpha]_D^{20} = -36.5$ (*c* 1, MeOH)

Source of chirality: asymmetric catalysis

Absolute configuration: *S*




C₁₃H₁₄O₂
(S)-(-)-1-(6-Methoxy-2-naphthyl)ethanol

Ee >99% by HPLC on (Chiralcel® OD-H) column

$[\alpha]_D^{20} = -36.4$ (*c* 0.8, EtOH)

Source of chirality: asymmetric catalysis

Absolute configuration: *S*




C₁₂H₁₂O
(S)-(-)-1-(1-Naphthyl)ethanol

Ee >99% by HPLC on (Chiralcel® OD-H) column

$[\alpha]_D^{20} = -66.5$ (*c* 1, MeOH)

Source of chirality: asymmetric catalysis

Absolute configuration: *S*



C₁₂H₁₀O
(S)-(+)-1-Acenaphthphenol

Ee >99% by HPLC on (Chiralcel® OD-H) column

$[\alpha]_D^{20} = +1.4$ (*c* 2.6, CHCl₃)


Source of chirality: asymmetric catalysis

Absolute configuration: *S*

Ee >99% by HPLC on (Chiralcel® OB-H) column

 $[\alpha]_D^{20} = -41.5$ (*c* 0.8, MeOH)

Source of chirality: asymmetric catalysis


Absolute configuration: *S*

(S)-(-)-1-Phenylethanol

Ee >99% by HPLC on (Chiralcel® OB-H) column

 $[\alpha]_D^{20} = -43.5$ (*c* 0.7, MeOH)

Source of chirality: asymmetric catalysis


Absolute configuration: *S*

(S)-(-)-1-(4-Methoxyphenyl)ethanol

Ee >99% by HPLC on (Chiralcel® OD-H) column

 $[\alpha]_D^{20} = +110.1$ (*c* 2, CHCl₃)

Source of chirality: asymmetric catalysis


Absolute configuration: *R*

(R)-(+)-Indan-1-yl acetate


Ee >99% by HPLC on (Chiralcel® OB-H) column

 $[\alpha]_D^{20} = +112.8$ (*c* 2, CHCl₃)

Source of chirality: asymmetric catalysis

Absolute configuration: *R*

(R)-(+)-1,2,3,4-Tetrahydro-1-naphthalenol acetate


 $C_{14}H_{14}O_2$

(R)-(+)-1-(2-Naphthyl)ethyl acetate

Ee >99% by HPLC on (Chiralcel® OD-H) column

 $[\alpha]_D^{20} = +110.2$ (*c* 1, CHCl₃)

Source of chirality: asymmetric catalysis


Absolute configuration: *R* $C_{15}H_{16}O_3$

(R)-(+)-1-[2-(6-Methoxynaphthyl)]ethyl acetate

Ee >99% by HPLC on (Chiralcel® OD-H) column

 $[\alpha]_D^{20} = +110$ (*c* 1, EtOH)

Source of chirality: asymmetric catalysis


Absolute configuration: *R* $C_{14}H_{14}O_2$

(R)-(+)-1-(1-Naphthyl)ethyl acetate

Ee >99% by HPLC on (Chiralcel® OD-H) column

 $[\alpha]_D^{20} = +49.5$ (*c* 1, CHCl₃)

Source of chirality: asymmetric catalysis

Absolute configuration: *R* $C_{14}H_{12}O_2$


(R)-(+)-1-Acenaphthylenol-1,2-dihydro acetate

Ee >99% by HPLC on (Chiralcel® OD-H) column

 $[\alpha]_D^{20} = +85.9$ (*c* 2.4, CHCl₃)

Source of chirality: asymmetric catalysis

Absolute configuration: *R*




$C_{10}H_{12}O_2$
(*R*)-(+)-1-Phenylethyl acetate

Ee >99% by HPLC on (Chiralcel® OB-H) column

$[\alpha]_D^{20} = +135.9$ (*c* 1, CHCl₃)

Source of chirality: asymmetric catalysis

Absolute configuration: *R*




$C_{11}H_{14}O_3$
(*R*)-(+)-1-(4-Methoxyphenyl)ethyl acetate

Ee = 91% by HPLC on (Chiralcel® OB-H) column

$[\alpha]_D^{20} = +123.6$ (*c* 1.2, CHCl₃)

Source of chirality: asymmetric catalysis

Absolute configuration: *R*




$C_{40}H_{42}N_4$
(-)-(4*S*,5*S*)-1,3-Dimethyl-2-(2-((4*S*,5*S*)-1,3-dimethyl-4,5-diphenylimidazolidin-2-yl)phenyl)-4,5-diphenylimidazolidine

Ee = 99%

$[\alpha]_D^{22} = -89.8$ (*c* 0.44, CHCl₃)

Source of chirality: resolution

Absolute configuration: (S,S)




$C_{24}H_{28}N_4$
(+)-(3*a**R*,7*a**R*)-Octahydro-2-(2-((3*a**R*,7*a**R*)-octahydro-1,3-dimethyl-1*H*-benzo[d]imidazol-2-yl)phenyl)-1,3-dimethyl-1*H*-benzo[d]-imidazole

Ee = 99%

$[\alpha]_D^{22} = +103.6$ (*c* 1.48, CHCl₃)

Source of chirality: resolution

Absolute configuration: (R,R)





(*-*)-(4*S*,5*S*)-1,3-Dimethyl-2-(2-((4*S*,5*S*)-1,3-dimethyl-4,5-diphenylimidazolidin-2-yl)phenyl)-4,5-diphenylimidazolinium bis-tetrakis-(3,5-bis(trifluoromethyl)phenyl)borate

Ee = 99%

 $[\alpha]_D^{22} = -25$ (*c* 0.45, acetone)

Source of chirality: resolution


Absolute configuration: (*S,S*)

(*-*)-(4*R*,5*R*)-1,3-Dimethyl-2-(2-((4*R*,5*R*)-1,3-dimethyl-4,5-diphenylimidazolidin-2-yl)phenyl)-4,5-diphenylimidazolinium bis-tetrakis-(3,5-bis(trifluoromethyl)phenyl)borate


Ee = 99%

 $[\alpha]_D^{22} = -5.9$ (*c* 0.67, acetone)

Source of chirality: resolution


Absolute configuration: (*R,R*)

(*S*)-2-(Pyrrolidin-1-ylmethyl)-pyrrolidine-1-carbonitrile



 $[\alpha]_D^{rt} = -50.2$ (*c* 2.95, CHCl₃)Source of chirality: (*S*)-2-(pyrrolidin-1-ylmethyl)-pyrrolidineAbsolute configuration: 2*S*

(*S*)-2-(Morpholin-4-ylmethyl)-pyrrolidine-1-carbonitrile



 $[\alpha]_D^{rt} = -40.5$ (*c* 2.37, CHCl₃)Source of chirality: 4-(pyrrolidin-(*S*)-2-ylmethyl)-morpholineAbsolute configuration: 2*S*





(S)-2-(Piperidin-1-ylmethyl)-pyrrolidine-1-carbonitrile

 $[\alpha]_D^{rt} = -50.8$ (*c* 2.71, CH₂Cl₂)Source of chirality: 1-(pyrrolidin-(*S*)-2-ylmethyl)-piperidineAbsolute configuration: 2*S*

C-Pyrrolidin-1-yl-C-(2-(pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl)-methylenamine


 $[\alpha]_D^{rt} = -22.2$ (*c* 2.47, CH₂Cl₂)Source of chirality: (*S*)-2-(pyrrolidin-1-ylmethyl)-pyrrolidineAbsolute configuration: 2*S*

C-(2-(Morpholin-4-ylmethyl)-pyrrolidin-1-yl)-C-pyrrolidin-1-yl-methylenamine


 $[\alpha]_D^{rt} = -18.9$ (*c* 3.49, CH₂Cl₂)Source of chirality: 4-(pyrrolidin-(*S*)-2-ylmethyl)-morpholineAbsolute configuration: 2*S*

C-(2-(Piperidin-1-ylmethyl)-pyrrolidin-1-yl)-C-pyrrolidin-1-yl-methylenamine


 $[\alpha]_D^{rt} = -21.5$ (*c* 3.08, CH₂Cl₂)Source of chirality: 1-(pyrrolidin-(*S*)-2-ylmethyl)-piperidineAbsolute configuration: 2*S*

 $C_{14}H_{26}N_4O$


C-Morpholin-4-yl-C-(2-(pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl)-methylenamine

 $[\alpha]_D^{rt} = +27.7$ (*c* 2.60, CH₂Cl₂)Source of chirality: (*S*)-2-(pyrrolidin-1-ylmethyl)-pyrrolidine
Absolute configuration: 2*S* $C_{14}H_{26}N_4O_2$

C-Morpholin-4-yl-C-(2-(morpholin-4-ylmethyl)-pyrrolidin-1-yl)-methylenamine




 $[\alpha]_D^{rt} = +26.2$ (*c* 2.60, CH₂Cl₂)Source of chirality: 4-(pyrrolidin-(*S*)-2-ylmethyl)-morpholine
Absolute configuration: 2*S* $C_{15}H_{28}N_4O$


C-Morpholin-4-yl-C-(2-(piperidin-1-ylmethyl)-pyrrolidin-1-yl)-methylenamine

 $[\alpha]_D^{rt} = +23.1$ (*c* 2.60, CH₂Cl₂)Source of chirality: 1-(pyrrolidin-(*S*)-2-ylmethyl)-piperidine
Absolute configuration: 2*S* $C_{15}H_{28}N_4$


C-Piperidin-1-yl-C-(2-(pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl)-methylenamine

 $[\alpha]_D^{rt} = +54.2$ (*c* 2.40, CH₂Cl₂)Source of chirality: (*S*)-2-(pyrrolidin-1-ylmethyl)-pyrrolidine
Absolute configuration: 2*S*


*C*-(2-(Morpholin-4-ylmethyl)-pyrrolidin-1-yl)-*C*-piperidin-1-yl-methylenamine $[\alpha]_D^{rt} = +51.7$ (*c* 2.32, CH₂Cl₂)Source of chirality: 4-(pyrrolidin-(*S*)-2-ylmethyl)-morpholineAbsolute configuration: 2*S**C*-Piperidin-1-yl-*C*-(2-(piperidin-1-ylmethyl)-pyrrolidin-1-yl)-methylenamine $[\alpha]_D^{rt} = +34.3$ (*c* 3.45, CH₂Cl₂)Source of chirality: 1-(pyrrolidin-(*S*)-2-ylmethyl)-piperidineAbsolute configuration: 2*S**C*-[Bis-(2-(pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl)]-methylenamine $[\alpha]_D^{rt} = -40.8$ (*c* 3.19, CH₂Cl₂)Source of chirality: (*S*)-2-(pyrrolidin-1-ylmethyl)-pyrrolidineAbsolute configuration: 2*S**C*-[Bis-(2-(morpholin-4-ylmethyl)-pyrrolidin-1-yl)]-methylenamine $[\alpha]_D^{rt} = -49.3$ (*c* 2.23, CH₂Cl₂)Source of chirality: 4-(pyrrolidin-(*S*)-2-ylmethyl)-morpholineAbsolute configuration: 2*S*

 $C_{21}H_{39}N_5$


C-[Bis-(2-(piperidin-1-ylmethyl)-pyrrolidin-1-yl)-methylene]amine

 $[\alpha]_D^{rt} = -40.4$ (*c* 3.66, CH_2Cl_2)Source of chirality: 1-(pyrrolidin-(*S*)-2-ylmethyl)-piperidine
Absolute configuration: 2*S* $C_{11}H_{16}O_5$ (1*R*,2*R*,3*S*,4*R*)-(E)-5,6,8-Trideoxy-1,2-*O*-isopropylidene- α -D-xylo-oct-5-eno-1,4-furanos-7-ulose $[\alpha]_D^{28} = -59.8$ (*c* 0.57, CHCl_3)

Source of chirality: D-glucose

Absolute configuration: (1*R*,2*R*,3*S*,4*R*) $C_9H_{14}O_3$ (1*S*,2*R*,5*R*,7*S*)-*exo*-2-Hydroxy-5-methyl-7-vinyl-6,8-dioxabicyclo[3.2.1]octane $[\alpha]_D^{26.4} = -42.7$ (*c* 0.53, CHCl_3)


Source of chirality: D-glucose

Absolute configuration: (1*S*,2*R*,5*R*,7*S*) $C_{30}H_{42}N_2O_6S_2$ (-)-[(2*R*,3*R*)-Bicyclo[2.2.2]oct-5-ene-2,3-diyl]bis[[3a*S*,6*S*,7a*R*)-1,4,5,6,7,7*a*-hexahydro-7,7-dimethyl-2,2-dioxido-3*H*-3*a*,6-methano-2,1-benzothiazol-1-yl]methanone]

Ee = 100%


 $[\alpha]_D^{20} = -88.7$ (*c* 0.5, CHCl_3)

Source of chirality: (-)-fenchone




($-$)-[(2*S*,3*S*)-Bicyclo[2.2.2]oct-5-ene-2,3-diyil]bis[(3a*S*,6*S*,7a*R*)-1,4,5,6,7,7a-hexahydro-7,7-dimethyl-2,2-dioxido-3*H*-3a,6-methano-2,1-benzothiazol-1-yl]methanone]

Ee = 100%
 $[\alpha]_D^{20} = -4.5$ (*c* 0.6, CHCl₃)
 Source of chirality: ($-$)-fenchone




Methyl (*Z*)-3-[(4*R*,5*S*)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-propenoate

Ee = 100%
 $[\alpha]_D^{25} = -140$ (*c* 1.2, CHCl₃)
 Source of chirality: asymmetric synthesis
 Absolute configuration: (4*R*,5*S*)




Methyl (*Z*)-3-[(4*R*,5*R*)-5-formyl-2,2-dimethyl-1,3-dioxolan-4-yl]-2-propenoate

Ee = 100%
 $[\alpha]_D^{25} = +16.3$ (*c* 0.65, CHCl₃)
 Source of chirality: asymmetric synthesis
 Absolute configuration: (4*R*,5*R*)



(3a*R*,4*R*,6a*S*)-4-(2-Methoxy-2-oxoethyl)-2,2-dimethyl-4,6a-dihydro-3a*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-ium-5-olate

Ee = 100%
 $[\alpha]_D^{25} = +11.0$ (*c* 0.96, CHCl₃)
 Source of chirality: asymmetric synthesis
 Absolute configuration: (3a*R*,4*R*,6a*S*)




(*Z*)-*tert*-Butyl-3-{(4*S*,5*R*)-5-[(1*R*)-1,2-dihydroxyethyl]-2,2-dimethyl-1,3-dioxolan-4-yl}-2-propenoates

Ee = 100%

$[\alpha]_D^{25} = +92.3$ (*c* 1.24, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (3*aR*,5*R*,5(*1R*))




(*Z*)-*tert*-Butyl-3-[(4*S*,5*S*)-5-formyl-2,2-dimethyl-1,3-dioxolan-4-yl]-2-propenoate

Ee = 100%

$[\alpha]_D^{25} = +92.3$ (*c* 1.24, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (4*S*,5*S*)




(3*aS*,4*S*,6*aR*)-4-[2-(*tert*-Butoxy)-2-oxoethyl]-2,2-dimethyl-4,6*a*-dihydro-3*aH*-[1,3]dioxolo[4,5-*c*]pyrrol-5-i um-5-olate

Ee = 100%

$[\alpha]_D^{25} = -3.1$ (*c* 3.4, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (3*aS*,4*S*,6*aR*)



(3*aS*,4*R*,6*aR*)-4-[2-(*tert*-butoxy)-2-oxoethyl]-2,2-dimethyl-4,6*a*-dihydro-3*aH*-[1,3]dioxolo[4,5-*c*]pyrrol-5-i um-5-olate

Ee = 100%


$[\alpha]_D^{25} = -62.1$ (*c* 1.76, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (3*aS*,4*R*,6*aR*)

Nikolaos G. Argyropoulos,* Theodoros D. Panagiotidis
and John K. Gallos

Tetrahedron: Asymmetry 17 (2006) 829



Ee = 100%

[α]_D²⁵ = +5 (c 0.38, CHCl₃)


Source of chirality: asymmetric synthesis

Absolute configuration: (3aS,4R,6aR)

(3aS,4S,6aR)-4-(2-Methoxy-2-oxoethyl)-2,2-dimethyl-6-[(trityloxy)methyl]-4,6a-dihydro-3aH-[1,3]dioxolo[4,5-c]pyrrol-5-ium-5-olate

Lara De Benassuti, Paola Del Buttero and Giorgio Molteni*

Tetrahedron: Asymmetry 17 (2006) 842



N,N-Diallyl-(S)-phenylglycine methylester


[α]_D²⁵ = -23.7 (c 0.26, CH₂Cl₂)

Source of chirality: (S)-phenylglycine methylester

Absolute configuration: (2S)

Lara De Benassuti, Paola Del Buttero and Giorgio Molteni*

Tetrahedron: Asymmetry 17 (2006) 842



N-2(S)-Diallylaminopropanoyl-N'-phenylhydrazine


[α]_D²⁵ = -16.4 (c 0.24, CHCl₃)

Source of chirality: N,N-diallyl-(S)-alanine methylester

Absolute configuration: (2S)

Lara De Benassuti, Paola Del Buttero and Giorgio Molteni*

Tetrahedron: Asymmetry 17 (2006) 842




N-2(S)-Diallylamino-3-phenyl-propanoyl-N'-phenylhydrazine


[α]_D²⁵ = -9.4 (c 0.15, CH₂Cl₂)

Source of chirality: N,N-diallyl-(S)-phenylalanine methylester


Absolute configuration: (2S)

*N*-2(*S*)-Diallylamino-2-phenyl-ethanoyl-*N'*-phenylhydrazine


$[\alpha]_D^{25} = -12.2$ (*c* 0.21, CH₂Cl₂)
 Source of chirality: *N,N*-diallyl-(*S*)-phenylglycine methylester
 Absolute configuration: (2*S*)

2-Phenyl-5-allyl-3a(*R*)-6(*S*)-methyl-2,3,3a,4,5,6-hexahydro-pyrrolo[3,4-*c*]pyrazole


$[\alpha]_D^{25} = -106.0$ (*c* 0.43, CH₂Cl₂)
 Source of chirality: the precursor
 Absolute configuration: 3a(*R*),6(*S*)

2-Phenyl-5-allyl-3a(*S*)-6(*S*)-benzyl-2,3,3a,4,5,6-hexahydro-pyrrolo[3,4-*c*]pyrazole

$[\alpha]_D^{25} = -83.2$ (*c* 0.51, CHCl₃)
 Source of chirality: the precursor
 Absolute configuration: 3a(*R*),6(*S*)

2-Phenyl-5-allyl-3a(*R*)-6(*S*)-phenyl-2,3,3a,4,5,6-hexahydro-pyrrolo[3,4-*c*]pyrazole

$[\alpha]_D^{25} = -76.1$ (*c* 0.29, CHCl₃)
 Source of chirality: the precursor
 Absolute configuration: 3a(*R*),6(*S*)




$C_{15}H_{19}N_3$
2-Phenyl-5-allyl-3a(*S*)-6(*S*)-methyl-2,3,3a,4,5,6-hexahydro-pyrrolo[3,4-*c*]pyrazole

$[\alpha]_D^{25} = +112.7$ (*c* 0.58, CHCl₃)

Source of chirality: the precursor

Absolute configuration: 3a(*S*),6(*S*)




$C_7H_{15}NO_2$
3-Ethyl-L-norvaline

Ee = 100%

$[\alpha]_D^{25} = +40$ (*c* 0.5, 5 M HCl)

Source of chirality: asymmetric synthesis

Absolute configuration: (*S*)




$C_{15}H_{22}N_2$
(2*S*)-3-Ethyl-2-{[(1*S*)-1-phenylethyl]amino}pentanenitrile

Ee = 100%

$[\alpha]_D^{25} = -187.4$ (*c* 1.0, MeOH)

Source of chirality: asymmetric synthesis

Absolute configuration: (1*S*,2*S*)




$C_{13}H_{21}NO_5$
(+)-(4*R*,5*R*)-5-(Pent-4-enoyl)-*N*-methoxy-*N*,2,2-trimethyl-1,3-dioxolane-4-carboxamide

$[\alpha]_D = +4.4$ (*c* 3.6, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (4*R*,5*R*)




$C_{19}H_{37}NO_5Si$
(-)-(4R,5R)-5-((R)-1-tert-Butyldimethylsilyloxypent-4-enyl)-N-methoxy-N,2,2-trimethyl-1,3-dioxolane-4-carboxamide

$[\alpha]_D = -9.5$ (*c* 2.1, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (4*R*,5*R*)




$C_{18}H_{34}NO_4Si$
(+)-(4R,5R)-5-((R)-1-tert-Butyldimethylsilyloxypent-4-enyl)-4-acetyl-2,2-dimethyl-1,3-dioxolane

$[\alpha]_D = +12.7$ (*c* 1.1, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (4*R*,5*R*)




$C_{17}H_{30}O_4$
(-)-2-Hydroxy-exo-brevicomin

$[\alpha]_D = -32$ (*c* 0.5, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (1*S*,2*R*,5*R*,7*S*)




BDDNPAC
 $C_{16}H_{24}ClNO_2$

$[\alpha]_D^{20} = +48.8$ (*c* 1.184, EtOH)

Source of chirality: synthesis from *threo*-(1*S*,2*S*)-2-amino-1-(4'-nitrophenyl)-1,3-propanediol


Absolute configuration: (1*S*,2*S*)



$[\alpha]_D^{20} = -25.9$ (*c* 1.012, DMF)

Source of chirality: synthesis from BDDNPAC and racemic BINOL

Absolute configuration: (1*S*,2*S*,*S*)




(*S*)-(+)-*N,N*-Dimethyl- α -[2-(1-naphthalenylloxy)ethyl]benzenemethanamine or (*S*)-dapoxetine

Ee = 93% (HPLC, Chiralcel OD)

$[\alpha]_D^{20} = +62.5$ (*c* 0.3, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: *S*




(*S*)-(-)-*N*-(*O*-*tert*-Butyldimethylsilyl)-3-hydroxy-1-phenylpropylmethoxyacetamide

Ee = 93% (HPLC, Chiralcel OD)

$[\alpha]_D^{20} = -40.5$ (*c* 0.7, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: *S*




(*R*)-(+)-3-Amino-*O*-*tert*-butylsilyl-3-phenylpropan-1-ol

Ee = 58% (HPLC, Chiralcel OD)

$[\alpha]_D^{20} = +7.1$ (*c* 0.55, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: *R*




C₉H₁₃NO
(S)-(-)-3-Amino-3-phenylpropan-1-ol

Ee = 93% (HPLC, Chiralcel OD)

[α]_D²⁰ = -11.2 (c 0.5, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: *S*



C₁₁H₁₇NO
(S)-(+)-3-(*N,N*-Dimethylamino)-3-phenylpropan-1-ol

Ee = 93% (HPLC, Chiralcel OD)

[α]_D²⁰ = +38.0 (c 0.6, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: *S*